{"transactions":[{"id":4625592,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46543,"kind":"person","name":"Denton John Russel","position":1,"cik":"0002071923","reported_name":"Denton John Russel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-23T21:06:43.000Z","date":"2026-09-22","kind":"sale","planned":false,"acquired":false,"shares":7500,"price":31.8168,"value":238626.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.7750 to $31.8700, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired in a non-reportable transaction under the Caris Life Sciences, Inc. 2025 Employee Stock Purchase Plan (a tax-qualified plan) after the date of the reporting person's previous Form 4."}],"balance_after":174855,"source":{"system":"sec-edgar","filing":"0002071923-26-000007","document":"wk-form4_1790197601.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2071923/000207192326000007/wk-form4_1790197601.xml","form_type":"4"}},{"id":4622017,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46541,"kind":"person","name":"Brille Brian J","position":1,"cik":"0002071959","reported_name":"Brille Brian J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2026-09-17T22:08:31.000Z","date":"2026-09-17","kind":"exercise","planned":false,"acquired":false,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."}],"balance_after":1600000,"derivative":{"exercise_price":2.44,"expiration_date":"2028-01-14","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0002071959-26-000008","document":"wk-form4_1789682909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2071959/000207195926000008/wk-form4_1789682909.xml","form_type":"4"}},{"id":4622016,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46541,"kind":"person","name":"Brille Brian J","position":1,"cik":"0002071959","reported_name":"Brille Brian J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-17T22:08:31.000Z","date":"2026-09-17","kind":"sale","planned":false,"acquired":false,"shares":400000,"price":30.3302,"value":12132080.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.2100 to $30.5650, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":230303,"source":{"system":"sec-edgar","filing":"0002071959-26-000008","document":"wk-form4_1789682909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2071959/000207195926000008/wk-form4_1789682909.xml","form_type":"4"}},{"id":4622015,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46541,"kind":"person","name":"Brille Brian J","position":1,"cik":"0002071959","reported_name":"Brille Brian J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-09-17T22:08:31.000Z","date":"2026-09-17","kind":"exercise","planned":false,"acquired":true,"shares":400000,"price":2.44,"value":976000.0,"ownership":{"direct":true},"balance_after":630303,"source":{"system":"sec-edgar","filing":"0002071959-26-000008","document":"wk-form4_1789682909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2071959/000207195926000008/wk-form4_1789682909.xml","form_type":"4"}},{"id":4697,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option","published_at":"2026-09-04T20:59:59.000Z","date":"2026-09-04","kind":"exercise","planned":false,"acquired":false,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Exercise of stock options before their expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.44,"expiration_date":"2026-09-12","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0002071953-26-000007","document":"wk-form4_1788555596.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2071953/000207195326000007/wk-form4_1788555596.xml","form_type":"4"}},{"id":4696,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option","published_at":"2026-09-04T20:59:59.000Z","date":"2026-09-03","kind":"exercise","planned":false,"acquired":false,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Exercise of stock options before their expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option is fully vested and exercisable."}],"balance_after":250000,"derivative":{"exercise_price":2.44,"expiration_date":"2026-09-12","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0002071953-26-000007","document":"wk-form4_1788555596.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2071953/000207195326000007/wk-form4_1788555596.xml","form_type":"4"}},{"id":4695,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2026-09-04T20:59:59.000Z","date":"2026-09-04","kind":"sale","planned":false,"acquired":false,"shares":119212,"price":24.7552,"value":2951116.9024,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.5550 to $25.1200, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1182871,"source":{"system":"sec-edgar","filing":"0002071953-26-000007","document":"wk-form4_1788555596.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2071953/000207195326000007/wk-form4_1788555596.xml","form_type":"4"}},{"id":4694,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2026-09-04T20:59:59.000Z","date":"2026-09-04","kind":"exercise","planned":false,"acquired":true,"shares":250000,"price":2.44,"value":610000.0,"ownership":{"direct":true},"balance_after":1302083,"source":{"system":"sec-edgar","filing":"0002071953-26-000007","document":"wk-form4_1788555596.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2071953/000207195326000007/wk-form4_1788555596.xml","form_type":"4"}},{"id":4693,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2026-09-04T20:59:59.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":84900,"price":25.3201,"value":2149676.49,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.3200 to $25.3300, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1052083,"source":{"system":"sec-edgar","filing":"0002071953-26-000007","document":"wk-form4_1788555596.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2071953/000207195326000007/wk-form4_1788555596.xml","form_type":"4"}},{"id":4692,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2026-09-04T20:59:59.000Z","date":"2026-09-03","kind":"sale","planned":false,"acquired":false,"shares":393100,"price":24.7604,"value":9733313.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a broker-assisted sell-to-cover exercise of fully vested stock options scheduled to expire on September 12, 2026. The shares were sold solely to cover the aggregate exercise price and applicable tax withholding obligations. The Reporting Person retained all remaining shares acquired upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.3200 to $25.3100, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":1136983,"source":{"system":"sec-edgar","filing":"0002071953-26-000007","document":"wk-form4_1788555596.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2071953/000207195326000007/wk-form4_1788555596.xml","form_type":"4"}},{"id":4691,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2026-09-04T20:59:59.000Z","date":"2026-09-03","kind":"exercise","planned":false,"acquired":true,"shares":1000000,"price":2.44,"value":2440000.0,"ownership":{"direct":true},"balance_after":1530083,"source":{"system":"sec-edgar","filing":"0002071953-26-000007","document":"wk-form4_1788555596.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2071953/000207195326000007/wk-form4_1788555596.xml","form_type":"4"}},{"id":687134,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23442,"kind":"person","name":"CASTLEMAN PETER M","position":1,"cik":"0001239594","reported_name":"CASTLEMAN PETER M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-14T21:44:43.000Z","date":"2026-08-14","kind":"grant","planned":false,"acquired":true,"shares":13192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":29321,"source":{"system":"sec-edgar","filing":"0001239594-26-000008","document":"wk-form4_1786743879.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000123959426000008/wk-form4_1786743879.xml","form_type":"4"}},{"id":687133,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23441,"kind":"person","name":"PHILLIPS T DANNY","position":1,"cik":"0001239690","reported_name":"PHILLIPS T DANNY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-14T21:43:23.000Z","date":"2026-08-14","kind":"grant","planned":false,"acquired":true,"shares":13192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":133060,"source":{"system":"sec-edgar","filing":"0001239690-26-000005","document":"wk-form4_1786743801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000123969026000005/wk-form4_1786743801.xml","form_type":"4"}},{"id":687132,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23440,"kind":"person","name":"Minor Lloyd","position":1,"cik":"0002038687","reported_name":"Minor Lloyd","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-14T21:42:39.000Z","date":"2026-08-14","kind":"grant","planned":false,"acquired":true,"shares":13192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":31813,"source":{"system":"sec-edgar","filing":"0002038687-26-000007","document":"wk-form4_1786743756.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000203868726000007/wk-form4_1786743756.xml","form_type":"4"}},{"id":687131,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23439,"kind":"person","name":"Gilliam Joseph E","position":1,"cik":"0001705850","reported_name":"Gilliam Joseph E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-14T21:41:58.000Z","date":"2026-08-14","kind":"grant","planned":false,"acquired":true,"shares":13192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":29321,"source":{"system":"sec-edgar","filing":"0001705850-26-000025","document":"wk-form4_1786743716.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000170585026000025/wk-form4_1786743716.xml","form_type":"4"}},{"id":687130,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23438,"kind":"person","name":"Fredrickson David Paul","position":1,"cik":"0002071948","reported_name":"Fredrickson David Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-14T21:41:25.000Z","date":"2026-08-14","kind":"grant","planned":false,"acquired":true,"shares":13192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":31813,"source":{"system":"sec-edgar","filing":"0002071948-26-000005","document":"wk-form4_1786743682.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207194826000005/wk-form4_1786743682.xml","form_type":"4"}},{"id":687129,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23437,"kind":"person","name":"Vacirca Jeff L","position":1,"cik":"0001724161","reported_name":"Vacirca Jeff L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-14T21:40:33.000Z","date":"2026-08-14","kind":"grant","planned":false,"acquired":true,"shares":13192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":62863,"source":{"system":"sec-edgar","filing":"0001724161-26-000008","document":"wk-form4_1786743631.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000172416126000008/wk-form4_1786743631.xml","form_type":"4"}},{"id":687128,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23436,"kind":"person","name":"JOHANSEN LAURA I","position":1,"cik":"0001189395","reported_name":"JOHANSEN LAURA I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-14T21:39:42.000Z","date":"2026-08-14","kind":"grant","planned":false,"acquired":true,"shares":13192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":343897,"source":{"system":"sec-edgar","filing":"0001189395-26-000002","document":"wk-form4_1786743580.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000118939526000002/wk-form4_1786743580.xml","form_type":"4"}},{"id":687127,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23435,"kind":"person","name":"HALBERT JON","position":1,"cik":"0001189394","reported_name":"HALBERT JON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-14T21:38:55.000Z","date":"2026-08-14","kind":"grant","planned":false,"acquired":true,"shares":13192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":131813,"source":{"system":"sec-edgar","filing":"0001189394-26-000008","document":"wk-form4_1786743533.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000118939426000008/wk-form4_1786743533.xml","form_type":"4"}},{"id":710749,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23435,"kind":"person","name":"HALBERT JON","position":1,"cik":"0001189394","reported_name":"HALBERT JON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-13T11:06:08.000Z","date":"2026-05-15","kind":"purchase","planned":false,"acquired":true,"shares":68000,"price":14.56,"value":990080.0,"ownership":{"direct":false,"nature":"By LAH Investments, Ltd."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.49 to $14.60 inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes an aggregate of 11,598 shares received in pro rata distributions exempt pursuant to Rule 16a-9."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":704598,"source":{"system":"sec-edgar","filing":"0001189394-26-000005","document":"wk-form4_1783940766.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000118939426000005/wk-form4_1783940766.xml","form_type":"4"}},{"id":755377,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":42492,"kind":"person","name":"POSTE GEORGE","position":1,"cik":"0001180770","reported_name":"POSTE GEORGE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-02T21:44:17.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":1600,"price":15.62,"value":24992.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount reflects the previous transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust. Following the transfer, these shares are held indirectly by the Reporting Person through the family trust and are reflected in the indirect ownership line. The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities."}],"balance_after":17729,"source":{"system":"sec-edgar","filing":"0001180770-26-000003","document":"wk-form4_1780436653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000118077026000003/wk-form4_1780436653.xml","form_type":"4"}},{"id":755375,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":42490,"kind":"person","name":"Knowles Jonathan Kenneth Charles","position":1,"cik":"0001662103","reported_name":"Knowles Jonathan Kenneth Charles","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-02T21:43:00.000Z","date":"2026-05-29","kind":"grant","planned":false,"acquired":true,"shares":1600,"price":15.62,"value":24992.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026."}],"balance_after":308979,"source":{"system":"sec-edgar","filing":"0001662103-26-000002","document":"wk-form4_1780436576.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000166210326000002/wk-form4_1780436576.xml","form_type":"4"}},{"id":775469,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46543,"kind":"person","name":"Denton John Russel","position":1,"cik":"0002071923","reported_name":"Denton John Russel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-18T20:23:48.000Z","date":"2026-05-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":6047,"price":15.25,"value":92216.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld for the payment of taxes on the vesting and settlement of RSUs."}],"balance_after":181515,"source":{"system":"sec-edgar","filing":"0002071923-26-000005","document":"wk-form4_1779135826.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207192326000005/wk-form4_1779135826.xml","form_type":"4"}},{"id":775468,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46542,"kind":"person","name":"Power Luke Thomas","position":1,"cik":"0002072013","reported_name":"Power Luke Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-18T20:23:28.000Z","date":"2026-05-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":9771,"price":15.25,"value":149007.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld for the payment of taxes on the vesting and settlement of RSUs."}],"balance_after":153771,"source":{"system":"sec-edgar","filing":"0002072013-26-000004","document":"wk-form4_1779135806.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207201326000004/wk-form4_1779135806.xml","form_type":"4"}},{"id":775466,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2026-05-18T20:23:15.000Z","date":"2026-05-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":13856,"price":15.25,"value":211304.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld for the payment of taxes on the vesting and settlement of RSUs."}],"balance_after":530083,"source":{"system":"sec-edgar","filing":"0002071953-26-000004","document":"wk-form4_1779135792.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207195326000004/wk-form4_1779135792.xml","form_type":"4"}},{"id":775465,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46541,"kind":"person","name":"Brille Brian J","position":1,"cik":"0002071959","reported_name":"Brille Brian J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-18T20:23:02.000Z","date":"2026-05-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":13987,"price":15.25,"value":213301.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld for the payment of taxes on the vesting and settlement of RSUs."}],"balance_after":230303,"source":{"system":"sec-edgar","filing":"0002071959-26-000006","document":"wk-form4_1779135780.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207195926000006/wk-form4_1779135780.xml","form_type":"4"}},{"id":775587,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46557,"kind":"person","name":"HALBERT DAVID D","position":1,"cik":"0001034380","reported_name":"HALBERT DAVID D","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-05-18T16:22:10.000Z","date":"2026-05-15","kind":"tax_withholding","planned":false,"acquired":false,"shares":40712,"price":15.25,"value":620858.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares withheld for the payment of taxes on the vesting and settlement of RSUs."}],"balance_after":2574533,"source":{"system":"sec-edgar","filing":"0001034380-26-000004","document":"wk-form4_1779135727.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034380/000103438026000004/wk-form4_1779135727.xml","form_type":"4"}},{"id":782954,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23437,"kind":"person","name":"Vacirca Jeff L","position":1,"cik":"0001724161","reported_name":"Vacirca Jeff L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T12:22:31.000Z","date":"2026-05-11","kind":"purchase","planned":false,"acquired":true,"shares":31050,"price":16.149,"value":501426.45,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.13 to $16.15, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote"}],"balance_after":49671,"source":{"system":"sec-edgar","filing":"0001724161-26-000005","document":"wk-form4_1778588549.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000172416126000005/wk-form4_1778588549.xml","form_type":"4"}},{"id":851562,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46542,"kind":"person","name":"Power Luke Thomas","position":1,"cik":"0002072013","reported_name":"Power Luke Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-10T22:01:21.000Z","date":"2026-03-06","kind":"grant","planned":false,"acquired":true,"shares":63971,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":163542,"source":{"system":"sec-edgar","filing":"0002072013-26-000002","document":"wk-form4_1773180079.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207201326000002/wk-form4_1773180079.xml","form_type":"4"}},{"id":851561,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46543,"kind":"person","name":"Denton John Russel","position":1,"cik":"0002071923","reported_name":"Denton John Russel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-10T22:00:25.000Z","date":"2026-03-06","kind":"grant","planned":false,"acquired":true,"shares":63971,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":187562,"source":{"system":"sec-edgar","filing":"0002071923-26-000002","document":"wk-form4_1773180021.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207192326000002/wk-form4_1773180021.xml","form_type":"4"}},{"id":851560,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2026-03-10T21:59:58.000Z","date":"2026-03-06","kind":"grant","planned":false,"acquired":true,"shares":83162,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":543939,"source":{"system":"sec-edgar","filing":"0002071953-26-000002","document":"wk-form4_1773179995.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207195326000002/wk-form4_1773179995.xml","form_type":"4"}},{"id":851559,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46541,"kind":"person","name":"Brille Brian J","position":1,"cik":"0002071959","reported_name":"Brille Brian J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-10T21:59:34.000Z","date":"2026-03-06","kind":"grant","planned":false,"acquired":true,"shares":83162,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":244290,"source":{"system":"sec-edgar","filing":"0002071959-26-000004","document":"wk-form4_1773179971.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207195926000004/wk-form4_1773179971.xml","form_type":"4"}},{"id":851757,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46557,"kind":"person","name":"HALBERT DAVID D","position":1,"cik":"0001034380","reported_name":"HALBERT DAVID D","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-03-10T17:55:42.000Z","date":"2026-03-06","kind":"grant","planned":false,"acquired":true,"shares":320112,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":2615245,"source":{"system":"sec-edgar","filing":"0001034380-26-000002","document":"wk-form4_1773179739.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034380/000103438026000002/wk-form4_1773179739.xml","form_type":"4"}},{"id":874847,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23440,"kind":"person","name":"Minor Lloyd","position":1,"cik":"0002038687","reported_name":"Minor Lloyd","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-02T12:48:57.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":2492,"price":20.06,"value":49989.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026."}],"balance_after":18621,"source":{"system":"sec-edgar","filing":"0002038687-26-000004","document":"wk-form4_1772455734.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000203868726000004/wk-form4_1772455734.xml","form_type":"4"}},{"id":877754,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23437,"kind":"person","name":"Vacirca Jeff L","position":1,"cik":"0001724161","reported_name":"Vacirca Jeff L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-27T23:09:21.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":2492,"price":20.06,"value":49989.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026."}],"balance_after":18621,"source":{"system":"sec-edgar","filing":"0001724161-26-000002","document":"wk-form4_1772233759.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000172416126000002/wk-form4_1772233759.xml","form_type":"4"}},{"id":877753,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23438,"kind":"person","name":"Fredrickson David Paul","position":1,"cik":"0002071948","reported_name":"Fredrickson David Paul","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-27T23:08:53.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":2492,"price":20.06,"value":49989.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026."}],"balance_after":18621,"source":{"system":"sec-edgar","filing":"0002071948-26-000002","document":"wk-form4_1772233729.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207194826000002/wk-form4_1772233729.xml","form_type":"4"}},{"id":877751,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23435,"kind":"person","name":"HALBERT JON","position":1,"cik":"0001189394","reported_name":"HALBERT JON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-27T23:08:30.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":2492,"price":20.06,"value":49989.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026."}],"balance_after":118621,"source":{"system":"sec-edgar","filing":"0001189394-26-000002","document":"wk-form4_1772233706.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000118939426000002/wk-form4_1772233706.xml","form_type":"4"}},{"id":877752,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23441,"kind":"person","name":"PHILLIPS T DANNY","position":1,"cik":"0001239690","reported_name":"PHILLIPS T DANNY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-27T23:08:02.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":3739,"price":20.06,"value":75004.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026."}],"balance_after":119868,"source":{"system":"sec-edgar","filing":"0001239690-26-000002","document":"wk-form4_1772233679.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000123969026000002/wk-form4_1772233679.xml","form_type":"4"}},{"id":877748,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23442,"kind":"person","name":"CASTLEMAN PETER M","position":1,"cik":"0001239594","reported_name":"CASTLEMAN PETER M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-27T23:07:35.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":5509,"price":20.06,"value":110510.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued in lieu of cash compensation for 2025 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including February 25, 2026."}],"balance_after":24138,"source":{"system":"sec-edgar","filing":"0001239594-26-000005","document":"wk-form4_1772233651.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000123959426000005/wk-form4_1772233651.xml","form_type":"4"}},{"id":940206,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23442,"kind":"person","name":"CASTLEMAN PETER M","position":1,"cik":"0001239594","reported_name":"CASTLEMAN PETER M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-01-13T23:37:09.000Z","date":"2026-01-09","kind":"exercise","planned":false,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option is fully vested and exercisable. These securities were previously reported on the Reporting Person's Form 3."}],"balance_after":0,"derivative":{"exercise_price":18.6,"expiration_date":"2035-02-27","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001239594-26-000003","document":"wk-form4_1768347427.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000123959426000003/wk-form4_1768347427.xml","form_type":"4"}},{"id":940205,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23442,"kind":"person","name":"CASTLEMAN PETER M","position":1,"cik":"0001239594","reported_name":"CASTLEMAN PETER M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-13T23:37:09.000Z","date":"2026-01-09","kind":"exercise","planned":false,"acquired":true,"shares":2500,"price":18.6,"value":46500.0,"ownership":{"direct":true},"balance_after":18629,"source":{"system":"sec-edgar","filing":"0001239594-26-000003","document":"wk-form4_1768347427.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000123959426000003/wk-form4_1768347427.xml","form_type":"4"}},{"id":971594,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46542,"kind":"person","name":"Power Luke Thomas","position":1,"cik":"0002072013","reported_name":"Power Luke Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2025-12-13T00:39:15.000Z","date":"2025-12-11","kind":"exercise","planned":true,"acquired":false,"shares":37500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.44,"expiration_date":"2028-11-14","underlying":"Common Stock","underlying_shares":37500},"source":{"system":"sec-edgar","filing":"0002072013-25-000006","document":"wk-form4_1765586352.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207201325000006/wk-form4_1765586352.xml","form_type":"4"}},{"id":971593,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46542,"kind":"person","name":"Power Luke Thomas","position":1,"cik":"0002072013","reported_name":"Power Luke Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2025-12-13T00:39:15.000Z","date":"2025-12-11","kind":"exercise","planned":true,"acquired":false,"shares":24750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.44,"expiration_date":"2027-05-30","underlying":"Common Stock","underlying_shares":24750},"source":{"system":"sec-edgar","filing":"0002072013-25-000006","document":"wk-form4_1765586352.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207201325000006/wk-form4_1765586352.xml","form_type":"4"}},{"id":971592,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46542,"kind":"person","name":"Power Luke Thomas","position":1,"cik":"0002072013","reported_name":"Power Luke Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-13T00:39:15.000Z","date":"2025-12-11","kind":"sale","planned":true,"acquired":false,"shares":1400,"price":27.1554,"value":38017.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.11 to $27.20, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":99571,"source":{"system":"sec-edgar","filing":"0002072013-25-000006","document":"wk-form4_1765586352.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207201325000006/wk-form4_1765586352.xml","form_type":"4"}},{"id":971591,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46542,"kind":"person","name":"Power Luke Thomas","position":1,"cik":"0002072013","reported_name":"Power Luke Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-13T00:39:15.000Z","date":"2025-12-11","kind":"sale","planned":true,"acquired":false,"shares":60850,"price":26.5644,"value":1616443.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.11 to $27.07, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":100971,"source":{"system":"sec-edgar","filing":"0002072013-25-000006","document":"wk-form4_1765586352.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207201325000006/wk-form4_1765586352.xml","form_type":"4"}},{"id":971590,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46542,"kind":"person","name":"Power Luke Thomas","position":1,"cik":"0002072013","reported_name":"Power Luke Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-13T00:39:15.000Z","date":"2025-12-11","kind":"exercise","planned":true,"acquired":true,"shares":37500,"price":2.44,"value":91500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025."}],"balance_after":161821,"source":{"system":"sec-edgar","filing":"0002072013-25-000006","document":"wk-form4_1765586352.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207201325000006/wk-form4_1765586352.xml","form_type":"4"}},{"id":971589,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46542,"kind":"person","name":"Power Luke Thomas","position":1,"cik":"0002072013","reported_name":"Power Luke Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-13T00:39:15.000Z","date":"2025-12-11","kind":"exercise","planned":true,"acquired":true,"shares":24750,"price":2.44,"value":60390.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option exercises and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 19, 2025."}],"balance_after":124321,"source":{"system":"sec-edgar","filing":"0002072013-25-000006","document":"wk-form4_1765586352.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207201325000006/wk-form4_1765586352.xml","form_type":"4"}},{"id":971588,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46541,"kind":"person","name":"Brille Brian J","position":1,"cik":"0002071959","reported_name":"Brille Brian J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-12T23:22:53.000Z","date":"2025-12-11","kind":"gift","planned":false,"acquired":false,"shares":650,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":161128,"source":{"system":"sec-edgar","filing":"0002071959-25-000009","document":"wk-form4_1765581770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207195925000009/wk-form4_1765581770.xml","form_type":"4"}},{"id":971587,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46541,"kind":"person","name":"Brille Brian J","position":1,"cik":"0002071959","reported_name":"Brille Brian J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-12-12T23:22:53.000Z","date":"2025-12-10","kind":"gift","planned":false,"acquired":false,"shares":650,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":161778,"source":{"system":"sec-edgar","filing":"0002071959-25-000009","document":"wk-form4_1765581770.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207195925000009/wk-form4_1765581770.xml","form_type":"4"}},{"id":1003943,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46543,"kind":"person","name":"Denton John Russel","position":1,"cik":"0002071923","reported_name":"Denton John Russel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-11-10T13:12:42.000Z","date":"2025-11-07","kind":"purchase","planned":false,"acquired":true,"shares":4184,"price":24.09,"value":100792.56,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.99 to $24.15, inclusive. The reporting person undertakes to provide to Caris Life Sciences, Inc., any security holder of Caris Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":9184,"source":{"system":"sec-edgar","filing":"0002071923-25-000009","document":"wk-form4_1762780360.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207192325000009/wk-form4_1762780360.xml","form_type":"4"}},{"id":1003939,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-11-10T13:11:33.000Z","date":"2025-11-07","kind":"purchase","planned":false,"acquired":true,"shares":400,"price":23.85,"value":9540.0,"ownership":{"direct":true},"balance_after":460777,"source":{"system":"sec-edgar","filing":"0002071953-25-000008","document":"wk-form4_1762780290.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000207195325000008/wk-form4_1762780290.xml","form_type":"4"}},{"id":1041814,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23441,"kind":"person","name":"PHILLIPS T DANNY","position":1,"cik":"0001239690","reported_name":"PHILLIPS T DANNY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-09-12T20:29:39.000Z","date":"2025-09-11","kind":"exercise","planned":false,"acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.44,"expiration_date":"2025-09-15","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001239690-25-000008","document":"wk-form4_1757708977.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000123969025000008/wk-form4_1757708977.xml","form_type":"4"}},{"id":1041813,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23441,"kind":"person","name":"PHILLIPS T DANNY","position":1,"cik":"0001239690","reported_name":"PHILLIPS T DANNY","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-12T20:29:39.000Z","date":"2025-09-11","kind":"exercise","planned":false,"acquired":true,"shares":100000,"price":2.44,"value":244000.0,"ownership":{"direct":true},"balance_after":116129,"source":{"system":"sec-edgar","filing":"0001239690-25-000008","document":"wk-form4_1757708977.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000123969025000008/wk-form4_1757708977.xml","form_type":"4"}},{"id":1068004,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":42492,"kind":"person","name":"POSTE GEORGE","position":1,"cik":"0001180770","reported_name":"POSTE GEORGE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-08-14T00:07:56.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.44,"expiration_date":"2025-09-15","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001104659-25-077777","document":"tm2523446-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925077777/tm2523446-3_4seq1.xml","form_type":"4"}},{"id":1068003,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":42492,"kind":"person","name":"POSTE GEORGE","position":1,"cik":"0001180770","reported_name":"POSTE GEORGE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-14T00:07:56.000Z","date":"2025-08-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":91495,"price":29.75,"value":2721976.25,"ownership":{"direct":true},"balance_after":220237,"source":{"system":"sec-edgar","filing":"0001104659-25-077777","document":"tm2523446-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925077777/tm2523446-3_4seq1.xml","form_type":"4"}},{"id":1068002,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":42492,"kind":"person","name":"POSTE GEORGE","position":1,"cik":"0001180770","reported_name":"POSTE GEORGE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-14T00:07:56.000Z","date":"2025-08-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":48022,"price":29.75,"value":1428654.5,"ownership":{"direct":true},"balance_after":311732,"source":{"system":"sec-edgar","filing":"0001104659-25-077777","document":"tm2523446-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925077777/tm2523446-3_4seq1.xml","form_type":"4"}},{"id":1068001,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":42492,"kind":"person","name":"POSTE GEORGE","position":1,"cik":"0001180770","reported_name":"POSTE GEORGE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-14T00:07:56.000Z","date":"2025-08-11","kind":"exercise","planned":false,"acquired":true,"shares":125000,"price":2.44,"value":305000.0,"ownership":{"direct":true},"balance_after":359754,"source":{"system":"sec-edgar","filing":"0001104659-25-077777","document":"tm2523446-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925077777/tm2523446-3_4seq1.xml","form_type":"4"}},{"id":1067999,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-08-14T00:07:06.000Z","date":"2025-08-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":63509,"price":29.75,"value":1889392.75,"ownership":{"direct":true},"balance_after":460377,"source":{"system":"sec-edgar","filing":"0001104659-25-077775","document":"tm2523446-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925077775/tm2523446-2_4seq1.xml","form_type":"4"}},{"id":1068133,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46557,"kind":"person","name":"HALBERT DAVID D","position":1,"cik":"0001034380","reported_name":"HALBERT DAVID D","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-08-13T20:05:16.000Z","date":"2025-08-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":141956,"price":29.75,"value":4223191.0,"ownership":{"direct":true},"balance_after":2295133,"source":{"system":"sec-edgar","filing":"0001104659-25-077773","document":"tm2523446-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034380/000110465925077773/tm2523446-1_4seq1.xml","form_type":"4"}},{"id":1104159,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option","published_at":"2025-06-23T22:41:24.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.44,"expiration_date":"2025-06-23","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001104659-25-061815","document":"tm2518641-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061815/tm2518641-9_4seq1.xml","form_type":"4"}},{"id":1104158,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option","published_at":"2025-06-23T22:41:24.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vested 60% at grant and will vest 20% on August 11, 2025 and 20% on August 11, 2026. These securities were previously reported on the Reporting Person's Form 3."}],"balance_after":750000,"derivative":{"exercise_price":18.6,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001104659-25-061815","document":"tm2518641-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061815/tm2518641-9_4seq1.xml","form_type":"4"}},{"id":1104157,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-06-23T22:41:24.000Z","date":"2025-06-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":34782,"price":27.25,"value":947809.5,"ownership":{"direct":true},"balance_after":523886,"source":{"system":"sec-edgar","filing":"0001104659-25-061815","document":"tm2518641-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061815/tm2518641-9_4seq1.xml","form_type":"4"}},{"id":1104156,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-06-23T22:41:24.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":true,"shares":75000,"price":2.44,"value":183000.0,"ownership":{"direct":true},"balance_after":558668,"source":{"system":"sec-edgar","filing":"0001104659-25-061815","document":"tm2518641-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061815/tm2518641-9_4seq1.xml","form_type":"4"}},{"id":1104155,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-06-23T22:41:24.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":132428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":483668,"source":{"system":"sec-edgar","filing":"0001104659-25-061815","document":"tm2518641-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061815/tm2518641-9_4seq1.xml","form_type":"4"}},{"id":1104154,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":10173,"kind":"person","name":"Spetzler David Baxley","position":1,"cik":"0002071953","reported_name":"Spetzler David Baxley","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-06-23T22:41:24.000Z","date":"2025-03-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":700509,"price":18.6,"value":13029467.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Common Stock surrendered to the Issuer as repayment for an outstanding promissory note."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 151,750 shares of Common Stock underlying restricted stock units which vest in accordance with the applicable grant agreements, which securities were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025."}],"balance_after":351240,"source":{"system":"sec-edgar","filing":"0001104659-25-061815","document":"tm2518641-9_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061815/tm2518641-9_4seq1.xml","form_type":"4"}},{"id":1104153,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46542,"kind":"person","name":"Power Luke Thomas","position":1,"cik":"0002072013","reported_name":"Power Luke Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-06-23T22:40:16.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":99321,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":99571,"source":{"system":"sec-edgar","filing":"0001104659-25-061814","document":"tm2518641-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061814/tm2518641-8_4seq1.xml","form_type":"4"}},{"id":1104152,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23435,"kind":"person","name":"HALBERT JON","position":1,"cik":"0001189394","reported_name":"HALBERT JON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2025-06-23T22:38:00.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":false,"shares":5000000,"ownership":{"direct":false,"nature":"By Ke'Ohana Ventures, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":1250000},"source":{"system":"sec-edgar","filing":"0001104659-25-061813","document":"tm2518641-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061813/tm2518641-7_4seq1.xml","form_type":"4"}},{"id":1104151,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23435,"kind":"person","name":"HALBERT JON","position":1,"cik":"0001189394","reported_name":"HALBERT JON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-23T22:38:00.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":true,"shares":1250000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Ke'Ohana Ventures, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":1250000,"source":{"system":"sec-edgar","filing":"0001104659-25-061813","document":"tm2518641-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061813/tm2518641-7_4seq1.xml","form_type":"4"}},{"id":1104150,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23435,"kind":"person","name":"HALBERT JON","position":1,"cik":"0001189394","reported_name":"HALBERT JON","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-23T22:38:00.000Z","date":"2025-02-27","kind":"grant","planned":false,"acquired":true,"shares":16129,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. These restricted stock units were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025."}],"balance_after":116129,"source":{"system":"sec-edgar","filing":"0001104659-25-061813","document":"tm2518641-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061813/tm2518641-7_4seq1.xml","form_type":"4"}},{"id":1104145,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78233,"kind":"person","name":"J H Whitney VI L P","position":1,"cik":"0001325073","reported_name":"J H Whitney VI L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78234,"kind":"organization","name":"J. H. Whitney Equity Partners VI, LLC","position":2,"cik":"0001394517","reported_name":"J. H. Whitney Equity Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20297,"kind":"person","name":"VIGANO PAUL R","position":3,"cik":"0001239606","reported_name":"VIGANO PAUL R","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20296,"kind":"person","name":"WILLIAMS ROBERT M JR","position":4,"cik":"0001239610","reported_name":"WILLIAMS ROBERT M JR","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2025-06-23T22:36:26.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":false,"shares":50067334,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by J.H. Whitney VI L.P. J.H. Whitney Equity Partners VI, LLC is the sole general partner of J.H. Whitney VI L.P. Paul R. Vigano and Robert M. Williams, Jr., as the managing members of J.H. Whitney Equity Partners VI, LLC, share voting and investment power with respect to the shares held by J.H. Whitney VI L.P. Each of J.H. Whitney Equity Partners VI, LLC, Paul R. Vigano and Robert M. Williams, Jr. disclaims beneficial ownership of such securities except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":12516834},"source":{"system":"sec-edgar","filing":"0001104659-25-061811","document":"tm2518641-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061811/tm2518641-6_4seq1.xml","form_type":"4"}},{"id":1104144,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78233,"kind":"person","name":"J H Whitney VI L P","position":1,"cik":"0001325073","reported_name":"J H Whitney VI L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78234,"kind":"organization","name":"J. H. Whitney Equity Partners VI, LLC","position":2,"cik":"0001394517","reported_name":"J. H. Whitney Equity Partners VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20297,"kind":"person","name":"VIGANO PAUL R","position":3,"cik":"0001239606","reported_name":"VIGANO PAUL R","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":20296,"kind":"person","name":"WILLIAMS ROBERT M JR","position":4,"cik":"0001239610","reported_name":"WILLIAMS ROBERT M JR","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-23T22:36:26.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":true,"shares":12516834,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities reported herein are held of record by J.H. Whitney VI L.P. J.H. Whitney Equity Partners VI, LLC is the sole general partner of J.H. Whitney VI L.P. Paul R. Vigano and Robert M. Williams, Jr., as the managing members of J.H. Whitney Equity Partners VI, LLC, share voting and investment power with respect to the shares held by J.H. Whitney VI L.P. Each of J.H. Whitney Equity Partners VI, LLC, Paul R. Vigano and Robert M. Williams, Jr. disclaims beneficial ownership of such securities except to the extent of its or his pecuniary interest therein."}],"balance_after":20256615,"source":{"system":"sec-edgar","filing":"0001104659-25-061811","document":"tm2518641-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061811/tm2518641-6_4seq1.xml","form_type":"4"}},{"id":1104149,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46543,"kind":"person","name":"Denton John Russel","position":1,"cik":"0002071923","reported_name":"Denton John Russel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option","published_at":"2025-06-23T22:34:51.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":255000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vested 60% at grant and will vest 20% on September 1, 2025 and 20% on September 1, 2026. These securities were previously reported on the Reporting Person's Form 3."}],"balance_after":255000,"derivative":{"exercise_price":18.6,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":255000},"source":{"system":"sec-edgar","filing":"0001104659-25-061810","document":"tm2518641-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061810/tm2518641-5_4seq1.xml","form_type":"4"}},{"id":1104148,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46543,"kind":"person","name":"Denton John Russel","position":1,"cik":"0002071923","reported_name":"Denton John Russel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-06-23T22:34:51.000Z","date":"2025-06-20","kind":"purchase","planned":false,"acquired":true,"shares":7500,"price":21,"value":157500.0,"ownership":{"direct":true},"balance_after":123591,"source":{"system":"sec-edgar","filing":"0001104659-25-061810","document":"tm2518641-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061810/tm2518641-5_4seq1.xml","form_type":"4"}},{"id":1104147,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46543,"kind":"person","name":"Denton John Russel","position":1,"cik":"0002071923","reported_name":"Denton John Russel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-06-23T22:34:51.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":99321,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":116091,"source":{"system":"sec-edgar","filing":"0001104659-25-061810","document":"tm2518641-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061810/tm2518641-5_4seq1.xml","form_type":"4"}},{"id":1104146,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46543,"kind":"person","name":"Denton John Russel","position":1,"cik":"0002071923","reported_name":"Denton John Russel","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-06-23T22:34:51.000Z","date":"2025-03-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":238230,"price":18.6,"value":4431078.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of Common Stock surrendered to the Issuer as repayment for an outstanding promissory note."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These securities were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025."}],"balance_after":16770,"source":{"system":"sec-edgar","filing":"0001104659-25-061810","document":"tm2518641-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061810/tm2518641-5_4seq1.xml","form_type":"4"}},{"id":1104143,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78231,"kind":"organization","name":"ADAPT I Ltd.","position":1,"cik":"0002072411","reported_name":"ADAPT I Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78232,"kind":"organization","name":"Carisome I, L.P.","position":2,"cik":"0002072412","reported_name":"Carisome I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2025-06-23T22:31:40.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":false,"shares":14000000,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Common Stock reported herein includes 8,528,805 shares of Common Stock held of record by ADAPT I Ltd. and 8,414,427 shares of Common Stock held of record by Carisome I, L.P. Two family trusts are separately the general partner of ADAPT I Ltd. and the managing general partner of Carisome I, L.P., respectively. David D. Halbert is the trustee of each of the two family trusts, and in such capacities, has voting and investment power with respect to the shares held of record by each of the foregoing entities. Mr. Halbert disclaims beneficial ownership except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The preferred stock reported herein includes 3,500,003 shares of Common Stock underlying Series A Preferred Stock held of record by ADAPT I Ltd.."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3500003},"source":{"system":"sec-edgar","filing":"0001104659-25-061805","document":"tm2518641-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061805/tm2518641-3_4seq1.xml","form_type":"4"}},{"id":1104142,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78231,"kind":"organization","name":"ADAPT I Ltd.","position":1,"cik":"0002072411","reported_name":"ADAPT I Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":78232,"kind":"organization","name":"Carisome I, L.P.","position":2,"cik":"0002072412","reported_name":"Carisome I, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-06-23T22:31:40.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":true,"shares":3500003,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Common Stock reported herein includes 8,528,805 shares of Common Stock held of record by ADAPT I Ltd. and 8,414,427 shares of Common Stock held of record by Carisome I, L.P. Two family trusts are separately the general partner of ADAPT I Ltd. and the managing general partner of Carisome I, L.P., respectively. David D. Halbert is the trustee of each of the two family trusts, and in such capacities, has voting and investment power with respect to the shares held of record by each of the foregoing entities. Mr. Halbert disclaims beneficial ownership except to the extent of his pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The preferred stock reported herein includes 3,500,003 shares of Common Stock underlying Series A Preferred Stock held of record by ADAPT I Ltd.."}],"balance_after":16943232,"source":{"system":"sec-edgar","filing":"0001104659-25-061805","document":"tm2518641-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061805/tm2518641-3_4seq1.xml","form_type":"4"}},{"id":1104141,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23442,"kind":"person","name":"CASTLEMAN PETER M","position":1,"cik":"0001239594","reported_name":"CASTLEMAN PETER M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2025-06-23T22:31:04.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":false,"shares":40983607,"ownership":{"direct":false,"nature":"By CLS-PF-SPE, LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"CLS-PF-SPE Manager, LLC is the manager of CLS-PF-SPE, LLC. Mr. Castleman is a manager of CLS-PF-SPE Manager, LLC and in such capacity has voting and investment power with respect to the shares held by CLS-PF-SPE, LLC. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":10245906},"source":{"system":"sec-edgar","filing":"0001104659-25-061804","document":"tm2518641-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061804/tm2518641-2_4seq1.xml","form_type":"4"}},{"id":1104140,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23442,"kind":"person","name":"CASTLEMAN PETER M","position":1,"cik":"0001239594","reported_name":"CASTLEMAN PETER M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-23T22:31:04.000Z","date":"2025-02-27","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option is fully vested and exercisable. These securities were previously reported on the Reporting Person's Form 3."}],"balance_after":2500,"derivative":{"exercise_price":18.6,"expiration_date":"2035-02-27","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001104659-25-061804","document":"tm2518641-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061804/tm2518641-2_4seq1.xml","form_type":"4"}},{"id":1104139,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23442,"kind":"person","name":"CASTLEMAN PETER M","position":1,"cik":"0001239594","reported_name":"CASTLEMAN PETER M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-23T22:31:04.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":true,"shares":10245906,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By CLS-PF-SPE, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"CLS-PF-SPE Manager, LLC is the manager of CLS-PF-SPE, LLC. Mr. Castleman is a manager of CLS-PF-SPE Manager, LLC and in such capacity has voting and investment power with respect to the shares held by CLS-PF-SPE, LLC. The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein."}],"balance_after":10270906,"source":{"system":"sec-edgar","filing":"0001104659-25-061804","document":"tm2518641-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061804/tm2518641-2_4seq1.xml","form_type":"4"}},{"id":1104138,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":23442,"kind":"person","name":"CASTLEMAN PETER M","position":1,"cik":"0001239594","reported_name":"CASTLEMAN PETER M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-23T22:31:04.000Z","date":"2025-02-27","kind":"grant","planned":false,"acquired":true,"shares":16129,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement. These restricted stock units were previously reported on the Reporting Person's Form 3. All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025."}],"balance_after":16129,"source":{"system":"sec-edgar","filing":"0001104659-25-061804","document":"tm2518641-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061804/tm2518641-2_4seq1.xml","form_type":"4"}},{"id":1104137,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46541,"kind":"person","name":"Brille Brian J","position":1,"cik":"0002071959","reported_name":"Brille Brian J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-06-23T22:30:15.000Z","date":"2025-06-20","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":21,"value":630000.0,"ownership":{"direct":true},"balance_after":162428,"source":{"system":"sec-edgar","filing":"0001104659-25-061802","document":"tm2518641-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061802/tm2518641-1_4seq1.xml","form_type":"4"}},{"id":1104136,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":46541,"kind":"person","name":"Brille Brian J","position":1,"cik":"0002071959","reported_name":"Brille Brian J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2025-06-23T22:30:15.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":132428,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units which vest in accordance with the applicable grant agreement."}],"balance_after":132428,"source":{"system":"sec-edgar","filing":"0001104659-25-061802","document":"tm2518641-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000110465925061802/tm2518641-1_4seq1.xml","form_type":"4"}},{"id":1104132,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"2020 Warrants","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":569991,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Sixth Street Specialty Lending, Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The 2020 warrants were exercisable into Series C preferred stock at a price of $1.93 per share and into Common Stock at a price of $7.73 per share. Immediately prior to and in connection with the closing of the Issuer's IPO the 2020 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock.  The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"kind","element":"transactionCoding","label":"F4","text":"The 2020 warrants were exercisable into Series C preferred stock at a price of $1.93 per share and into Common Stock at a price of $7.73 per share. Immediately prior to and in connection with the closing of the Issuer's IPO the 2020 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock.  The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The 2020 warrants were exercisable into Series C preferred stock at a price of $1.93 per share and into Common Stock at a price of $7.73 per share. Immediately prior to and in connection with the closing of the Issuer's IPO the 2020 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock.  The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The 2020 warrants were exercisable into Series C preferred stock at a price of $1.93 per share and into Common Stock at a price of $7.73 per share. Immediately prior to and in connection with the closing of the Issuer's IPO the 2020 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock.  The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"TSSP Holdco Management, LLC, a Delaware limited liability company (\"Holdco Management\"), manages Sixth Street Specialty Lending Advisers Holdings, LLC, a Delaware limited liability company (\"Adviser Holdings\"). The business and affairs of Sixth Street Specialty Lending Advisers, LLC, a Delaware limited liability company (\"Adviser\"), are managed by Adviser Holdings, the sole member of Adviser. Sixth Street Specialty Lending, Inc. is managed by Adviser."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"expiration_date":"2027-04-02","underlying":"Common Stock","underlying_shares":90059},"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}},{"id":1104131,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"2020 Warrants","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":10829823,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Barnett Equity Holdings, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The 2020 warrants were exercisable into Series C preferred stock at a price of $1.93 per share and into Common Stock at a price of $7.73 per share. Immediately prior to and in connection with the closing of the Issuer's IPO the 2020 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock.  The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"kind","element":"transactionCoding","label":"F4","text":"The 2020 warrants were exercisable into Series C preferred stock at a price of $1.93 per share and into Common Stock at a price of $7.73 per share. Immediately prior to and in connection with the closing of the Issuer's IPO the 2020 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock.  The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The 2020 warrants were exercisable into Series C preferred stock at a price of $1.93 per share and into Common Stock at a price of $7.73 per share. Immediately prior to and in connection with the closing of the Issuer's IPO the 2020 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock.  The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The 2020 warrants were exercisable into Series C preferred stock at a price of $1.93 per share and into Common Stock at a price of $7.73 per share. Immediately prior to and in connection with the closing of the Issuer's IPO the 2020 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock.  The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"TSSP Sub-Fund Holdco, LLC, a Delaware limited liability company (\"Sub-Fund HoldCo\"), is the sole member of each of TAO SPV GP, LLC, a Delaware limited liability company (\"TAO SPV\"), and Empire SPV GP, LLC, a Delaware limited liability company (\"Empire SPV\"). TAO SPV is the managing member of each of (i) Barnett Equity Holdings, LLC; (ii) Barnett Equity Holdings II LLC; and (iii) TAO Barnett Investments LLC. Empire SPV is the managing member of TOP III Barnett Investments, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"expiration_date":"2027-04-02","underlying":"Common Stock","underlying_shares":1711113},"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}},{"id":1104130,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"2018 Warrants","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":684731,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Sixth Street Specialty Lending, Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The 2018 warrants were exercisable at the option of the holder into shares of Series C Preferred Stock of the Issuer at an exercise price of $1.61 per share and into Common Stock at an exercise price of $6.44 per share. Immediately prior to and in connection with the closing of the Issuer's IPO, the 2018 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The 2018 warrants were exercisable at the option of the holder into shares of Series C Preferred Stock of the Issuer at an exercise price of $1.61 per share and into Common Stock at an exercise price of $6.44 per share. Immediately prior to and in connection with the closing of the Issuer's IPO, the 2018 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The 2018 warrants were exercisable at the option of the holder into shares of Series C Preferred Stock of the Issuer at an exercise price of $1.61 per share and into Common Stock at an exercise price of $6.44 per share. Immediately prior to and in connection with the closing of the Issuer's IPO, the 2018 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The 2018 warrants were exercisable at the option of the holder into shares of Series C Preferred Stock of the Issuer at an exercise price of $1.61 per share and into Common Stock at an exercise price of $6.44 per share. Immediately prior to and in connection with the closing of the Issuer's IPO, the 2018 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"TSSP Holdco Management, LLC, a Delaware limited liability company (\"Holdco Management\"), manages Sixth Street Specialty Lending Advisers Holdings, LLC, a Delaware limited liability company (\"Adviser Holdings\"). The business and affairs of Sixth Street Specialty Lending Advisers, LLC, a Delaware limited liability company (\"Adviser\"), are managed by Adviser Holdings, the sole member of Adviser. Sixth Street Specialty Lending, Inc. is managed by Adviser."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"expiration_date":"2025-09-20","underlying":"Common Stock","underlying_shares":118687},"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}},{"id":1104129,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"2018 Warrants","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":false,"shares":13009892,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Barnett Equity Holdings, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The 2018 warrants were exercisable at the option of the holder into shares of Series C Preferred Stock of the Issuer at an exercise price of $1.61 per share and into Common Stock at an exercise price of $6.44 per share. Immediately prior to and in connection with the closing of the Issuer's IPO, the 2018 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The 2018 warrants were exercisable at the option of the holder into shares of Series C Preferred Stock of the Issuer at an exercise price of $1.61 per share and into Common Stock at an exercise price of $6.44 per share. Immediately prior to and in connection with the closing of the Issuer's IPO, the 2018 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The 2018 warrants were exercisable at the option of the holder into shares of Series C Preferred Stock of the Issuer at an exercise price of $1.61 per share and into Common Stock at an exercise price of $6.44 per share. Immediately prior to and in connection with the closing of the Issuer's IPO, the 2018 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The 2018 warrants were exercisable at the option of the holder into shares of Series C Preferred Stock of the Issuer at an exercise price of $1.61 per share and into Common Stock at an exercise price of $6.44 per share. Immediately prior to and in connection with the closing of the Issuer's IPO, the 2018 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"TSSP Sub-Fund Holdco, LLC, a Delaware limited liability company (\"Sub-Fund HoldCo\"), is the sole member of each of TAO SPV GP, LLC, a Delaware limited liability company (\"TAO SPV\"), and Empire SPV GP, LLC, a Delaware limited liability company (\"Empire SPV\"). TAO SPV is the managing member of each of (i) Barnett Equity Holdings, LLC; (ii) Barnett Equity Holdings II LLC; and (iii) TAO Barnett Investments LLC. Empire SPV is the managing member of TOP III Barnett Investments, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"expiration_date":"2025-09-20","underlying":"Common Stock","underlying_shares":2255048},"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}},{"id":1104128,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series D Preferred Stock","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":false,"shares":23574073,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Barnett Equity Holdings II, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series D Preferred Stock of the Issuer was convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO. The Series D Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Series D Preferred Stock of the Issuer was convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO. The Series D Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series D Preferred Stock of the Issuer was convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO. The Series D Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series D Preferred Stock of the Issuer was convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO. The Series D Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each share of Series D Preferred Stock of the Issuer was convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO. The Series D Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"TSSP Sub-Fund Holdco, LLC, a Delaware limited liability company (\"Sub-Fund HoldCo\"), is the sole member of each of TAO SPV GP, LLC, a Delaware limited liability company (\"TAO SPV\"), and Empire SPV GP, LLC, a Delaware limited liability company (\"Empire SPV\"). TAO SPV is the managing member of each of (i) Barnett Equity Holdings, LLC; (ii) Barnett Equity Holdings II LLC; and (iii) TAO Barnett Investments LLC. Empire SPV is the managing member of TOP III Barnett Investments, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10103175},"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}},{"id":1104127,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series D Preferred Stock","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":false,"shares":1240740,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Sixth Street Specialty Lending, Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series D Preferred Stock of the Issuer was convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO. The Series D Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Series D Preferred Stock of the Issuer was convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO. The Series D Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series D Preferred Stock of the Issuer was convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO. The Series D Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series D Preferred Stock of the Issuer was convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO. The Series D Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each share of Series D Preferred Stock of the Issuer was convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO. The Series D Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"TSSP Holdco Management, LLC, a Delaware limited liability company (\"Holdco Management\"), manages Sixth Street Specialty Lending Advisers Holdings, LLC, a Delaware limited liability company (\"Adviser Holdings\"). The business and affairs of Sixth Street Specialty Lending Advisers, LLC, a Delaware limited liability company (\"Adviser\"), are managed by Adviser Holdings, the sole member of Adviser. Sixth Street Specialty Lending, Inc. is managed by Adviser."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":531746},"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}},{"id":1104126,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series C Preferred Stock","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":false,"shares":1915114,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Sixth Street Specialty Lending, Inc."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"TSSP Holdco Management, LLC, a Delaware limited liability company (\"Holdco Management\"), manages Sixth Street Specialty Lending Advisers Holdings, LLC, a Delaware limited liability company (\"Adviser Holdings\"). The business and affairs of Sixth Street Specialty Lending Advisers, LLC, a Delaware limited liability company (\"Adviser\"), are managed by Adviser Holdings, the sole member of Adviser. Sixth Street Specialty Lending, Inc. is managed by Adviser."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":478779},"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}},{"id":1104125,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series C Preferred Stock","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":false,"shares":13975155,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by TAO Barnett Investments LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"TSSP Sub-Fund Holdco, LLC, a Delaware limited liability company (\"Sub-Fund HoldCo\"), is the sole member of each of TAO SPV GP, LLC, a Delaware limited liability company (\"TAO SPV\"), and Empire SPV GP, LLC, a Delaware limited liability company (\"Empire SPV\"). TAO SPV is the managing member of each of (i) Barnett Equity Holdings, LLC; (ii) Barnett Equity Holdings II LLC; and (iii) TAO Barnett Investments LLC. Empire SPV is the managing member of TOP III Barnett Investments, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3493789},"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}},{"id":1104124,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series C Preferred Stock","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":false,"shares":15527951,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by TOP III Barnett Investments, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"TSSP Sub-Fund Holdco, LLC, a Delaware limited liability company (\"Sub-Fund HoldCo\"), is the sole member of each of TAO SPV GP, LLC, a Delaware limited liability company (\"TAO SPV\"), and Empire SPV GP, LLC, a Delaware limited liability company (\"Empire SPV\"). TAO SPV is the managing member of each of (i) Barnett Equity Holdings, LLC; (ii) Barnett Equity Holdings II LLC; and (iii) TAO Barnett Investments LLC. Empire SPV is the managing member of TOP III Barnett Investments, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3881988},"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}},{"id":1104123,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Series C Preferred Stock","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":false,"shares":6884058,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Held by Barnett Equity Holdings, LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"TSSP Sub-Fund Holdco, LLC, a Delaware limited liability company (\"Sub-Fund HoldCo\"), is the sole member of each of TAO SPV GP, LLC, a Delaware limited liability company (\"TAO SPV\"), and Empire SPV GP, LLC, a Delaware limited liability company (\"Empire SPV\"). TAO SPV is the managing member of each of (i) Barnett Equity Holdings, LLC; (ii) Barnett Equity Holdings II LLC; and (iii) TAO Barnett Investments LLC. Empire SPV is the managing member of TOP III Barnett Investments, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1721015},"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}},{"id":1104122,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":true,"shares":90059,"ownership":{"direct":false,"nature":"Held by Sixth Street Specialty Lending, Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The 2020 warrants were exercisable into Series C preferred stock at a price of $1.93 per share and into Common Stock at a price of $7.73 per share. Immediately prior to and in connection with the closing of the Issuer's IPO the 2020 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock.  The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"shares","element":"transactionShares","label":"F4","text":"The 2020 warrants were exercisable into Series C preferred stock at a price of $1.93 per share and into Common Stock at a price of $7.73 per share. Immediately prior to and in connection with the closing of the Issuer's IPO the 2020 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock.  The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The 2020 warrants were exercisable into Series C preferred stock at a price of $1.93 per share and into Common Stock at a price of $7.73 per share. Immediately prior to and in connection with the closing of the Issuer's IPO the 2020 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock.  The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"TSSP Holdco Management, LLC, a Delaware limited liability company (\"Holdco Management\"), manages Sixth Street Specialty Lending Advisers Holdings, LLC, a Delaware limited liability company (\"Adviser Holdings\"). The business and affairs of Sixth Street Specialty Lending Advisers, LLC, a Delaware limited liability company (\"Adviser\"), are managed by Adviser Holdings, the sole member of Adviser. Sixth Street Specialty Lending, Inc. is managed by Adviser."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":1219271,"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}},{"id":1104121,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":true,"shares":1711113,"ownership":{"direct":false,"nature":"Held by Barnett Equity Holdings, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The 2020 warrants were exercisable into Series C preferred stock at a price of $1.93 per share and into Common Stock at a price of $7.73 per share. Immediately prior to and in connection with the closing of the Issuer's IPO the 2020 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock.  The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"shares","element":"transactionShares","label":"F4","text":"The 2020 warrants were exercisable into Series C preferred stock at a price of $1.93 per share and into Common Stock at a price of $7.73 per share. Immediately prior to and in connection with the closing of the Issuer's IPO the 2020 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock.  The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The 2020 warrants were exercisable into Series C preferred stock at a price of $1.93 per share and into Common Stock at a price of $7.73 per share. Immediately prior to and in connection with the closing of the Issuer's IPO the 2020 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock.  The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"TSSP Sub-Fund Holdco, LLC, a Delaware limited liability company (\"Sub-Fund HoldCo\"), is the sole member of each of TAO SPV GP, LLC, a Delaware limited liability company (\"TAO SPV\"), and Empire SPV GP, LLC, a Delaware limited liability company (\"Empire SPV\"). TAO SPV is the managing member of each of (i) Barnett Equity Holdings, LLC; (ii) Barnett Equity Holdings II LLC; and (iii) TAO Barnett Investments LLC. Empire SPV is the managing member of TOP III Barnett Investments, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":5687176,"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}},{"id":1104120,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":true,"shares":118687,"ownership":{"direct":false,"nature":"Held by Sixth Street Specialty Lending, Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The 2018 warrants were exercisable at the option of the holder into shares of Series C Preferred Stock of the Issuer at an exercise price of $1.61 per share and into Common Stock at an exercise price of $6.44 per share. Immediately prior to and in connection with the closing of the Issuer's IPO, the 2018 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"shares","element":"transactionShares","label":"F3","text":"The 2018 warrants were exercisable at the option of the holder into shares of Series C Preferred Stock of the Issuer at an exercise price of $1.61 per share and into Common Stock at an exercise price of $6.44 per share. Immediately prior to and in connection with the closing of the Issuer's IPO, the 2018 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The 2018 warrants were exercisable at the option of the holder into shares of Series C Preferred Stock of the Issuer at an exercise price of $1.61 per share and into Common Stock at an exercise price of $6.44 per share. Immediately prior to and in connection with the closing of the Issuer's IPO, the 2018 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"TSSP Holdco Management, LLC, a Delaware limited liability company (\"Holdco Management\"), manages Sixth Street Specialty Lending Advisers Holdings, LLC, a Delaware limited liability company (\"Adviser Holdings\"). The business and affairs of Sixth Street Specialty Lending Advisers, LLC, a Delaware limited liability company (\"Adviser\"), are managed by Adviser Holdings, the sole member of Adviser. Sixth Street Specialty Lending, Inc. is managed by Adviser."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":1129212,"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}},{"id":1104119,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"other","planned":false,"acquired":true,"shares":2255048,"ownership":{"direct":false,"nature":"Held by Barnett Equity Holdings, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The 2018 warrants were exercisable at the option of the holder into shares of Series C Preferred Stock of the Issuer at an exercise price of $1.61 per share and into Common Stock at an exercise price of $6.44 per share. Immediately prior to and in connection with the closing of the Issuer's IPO, the 2018 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"shares","element":"transactionShares","label":"F3","text":"The 2018 warrants were exercisable at the option of the holder into shares of Series C Preferred Stock of the Issuer at an exercise price of $1.61 per share and into Common Stock at an exercise price of $6.44 per share. Immediately prior to and in connection with the closing of the Issuer's IPO, the 2018 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The 2018 warrants were exercisable at the option of the holder into shares of Series C Preferred Stock of the Issuer at an exercise price of $1.61 per share and into Common Stock at an exercise price of $6.44 per share. Immediately prior to and in connection with the closing of the Issuer's IPO, the 2018 warrants were exercised on a cashless basis into shares of Series C Preferred Stock which then automatically converted into Common Stock. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"TSSP Sub-Fund Holdco, LLC, a Delaware limited liability company (\"Sub-Fund HoldCo\"), is the sole member of each of TAO SPV GP, LLC, a Delaware limited liability company (\"TAO SPV\"), and Empire SPV GP, LLC, a Delaware limited liability company (\"Empire SPV\"). TAO SPV is the managing member of each of (i) Barnett Equity Holdings, LLC; (ii) Barnett Equity Holdings II LLC; and (iii) TAO Barnett Investments LLC. Empire SPV is the managing member of TOP III Barnett Investments, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":3976063,"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}},{"id":1104118,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":true,"shares":10103175,"ownership":{"direct":false,"nature":"Held by Barnett Equity Holdings II, LLC"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Series D Preferred Stock of the Issuer was convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO. The Series D Preferred Stock had no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each share of Series D Preferred Stock of the Issuer was convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO. The Series D Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series D Preferred Stock of the Issuer was convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO. The Series D Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"TSSP Sub-Fund Holdco, LLC, a Delaware limited liability company (\"Sub-Fund HoldCo\"), is the sole member of each of TAO SPV GP, LLC, a Delaware limited liability company (\"TAO SPV\"), and Empire SPV GP, LLC, a Delaware limited liability company (\"Empire SPV\"). TAO SPV is the managing member of each of (i) Barnett Equity Holdings, LLC; (ii) Barnett Equity Holdings II LLC; and (iii) TAO Barnett Investments LLC. Empire SPV is the managing member of TOP III Barnett Investments, LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":10103175,"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}},{"id":1104117,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":true,"shares":531746,"ownership":{"direct":false,"nature":"Held by Sixth Street Specialty Lending, Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Each share of Series D Preferred Stock of the Issuer was convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO. The Series D Preferred Stock had no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each share of Series D Preferred Stock of the Issuer was convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO. The Series D Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series D Preferred Stock of the Issuer was convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO. The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's Charter, in connection with the IPO. The Series D Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"TSSP Holdco Management, LLC, a Delaware limited liability company (\"Holdco Management\"), manages Sixth Street Specialty Lending Advisers Holdings, LLC, a Delaware limited liability company (\"Adviser Holdings\"). The business and affairs of Sixth Street Specialty Lending Advisers, LLC, a Delaware limited liability company (\"Adviser\"), are managed by Adviser Holdings, the sole member of Adviser. Sixth Street Specialty Lending, Inc. is managed by Adviser."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":1010525,"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}},{"id":1104116,"issuer":{"id":3706,"kind":"organization","name":"Caris Life Sciences, Inc.","symbol":"CAI"},"owners":[{"id":78230,"kind":"organization","name":"TSSP Sub-Fund HoldCo LLC","position":1,"cik":"0001677508","reported_name":"TSSP Sub-Fund HoldCo LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":1868,"kind":"person","name":"Waxman Alan","position":2,"cik":"0001515132","reported_name":"Waxman Alan","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}}],"security":"Common Stock","published_at":"2025-06-23T20:45:05.000Z","date":"2025-06-20","kind":"exercise","planned":false,"acquired":true,"shares":478779,"ownership":{"direct":false,"nature":"Held by Sixth Street Specialty Lending, Inc."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the \"Issuer\") was convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the \"Common Stock\") and automatically converted into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the \"IPO\"). The number of shares received upon conversion reflects certain adjustments pursuant to the terms of the Issuer's amended and restated certificate of formation (the \"Charter\"), in connection with the IPO. The Series C Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"TSSP Holdco Management, LLC, a Delaware limited liability company (\"Holdco Management\"), manages Sixth Street Specialty Lending Advisers Holdings, LLC, a Delaware limited liability company (\"Adviser Holdings\"). The business and affairs of Sixth Street Specialty Lending Advisers, LLC, a Delaware limited liability company (\"Adviser\"), are managed by Adviser Holdings, the sole member of Adviser. Sixth Street Specialty Lending, Inc. is managed by Adviser."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman (\"Mr. Waxman\"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein."}],"balance_after":478779,"source":{"system":"sec-edgar","filing":"0000950170-25-089040","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2019410/000095017025089040/ownership.xml","form_type":"4"}}],"next_cursor":"2025-06-23T20:45:05.000000Z,1104116"}